Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
38.00
+0.19 (0.50%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Cytokinetics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 81.63, with a low estimate of 54 and a high estimate of 120. The average target predicts an increase of 114.82% from the current stock price of 38.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Buy | 8 | 8 | 8 | 9 | 9 | 9 |
| Hold | 4 | 4 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +215.79% | Apr 21, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $62 → $54 | Hold | Maintains | $62 → $54 | +42.11% | Apr 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +215.79% | Apr 15, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $78 | Buy | Reiterates | $78 | +105.26% | Apr 10, 2025 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +89.47% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
28.79M
from 18.47M
Increased by 55.84%
Revenue Next Year
218.76M
from 28.79M
Increased by 659.85%
EPS This Year
-5.84
from -5.26
EPS Next Year
-4.78
from -5.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 67.3M | 415.8M | 827.5M | ||
| Avg | 28.8M | 218.8M | 509.7M | ||
| Low | 6.4M | 101.2M | 340.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 264.3% | 1,344.3% | 278.3% | ||
| Avg | 55.8% | 659.8% | 133.0% | ||
| Low | -65.5% | 251.6% | 55.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.15 | -3.38 | -0.72 | ||
| Avg | -5.84 | -4.78 | -2.50 | ||
| Low | -6.56 | -6.37 | -4.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.